Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis | Coherent Market Insights

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS
INJECTION MARKET ANALYSIS

• Human Immunoglobulin (pH4) for Intravenous
  injection (COVID-19) Market,By Type (IgG, IgA,
  and IgM), By Disease Indication (COVID-19,Primary
  Immunodeficiency Disease,Immune-mediated
  Thrombocytopenia, Kawasaki Disease,B Chronic
  lymphocytic Leukemia(B-CLL),and Others),By
  Distribution Channel (Hospital Pharmacies, Retail
  Pharmacies, and Online Pharmacies) and by Region
  (North America, Latin America, Europe, Asia
  Pacific, Middle East, and Africa) - Size,
  Share,Outlook, and Opportunity Analysis, 2020 -
  2027

3

• The global human immunoglobulin (pH4) for
• intravenous injection (COVID-19) market is
  estimated to be valued at US 43,205.84 million
  in 2020 and is expected to exhibit a CAGR of
  12.7 during the forecast period (2020-2027).
• Drivers
• Human immunoglobulin is a sterile solution made
  from human plasma. Diseases such as primary
  immunodeficiency are treated by administering
  human immunoglobulin through intravenous
  injection (IGIV). Human immunoglobulin also helps
  in increasing the platelets (blood clotting
  cells) in people with immune thrombocytopenic
  purpura and prevents infections in people with
  B-cell chronic lymphocytic leukemia. Patients of
  Kawasaki syndrome are administered human
  immunoglobulin to prevent aneurysm caused due to
  weakening of the main artery in the heart.

4

• Furthermore, intravenous human immunoglobulin
  (pH4) is being extensively researched in order to
  develop a treatment of COVID-19. This is likely
  to drive demand of human immunoglobulin (pH4) for
  intravenous injection and boost the growth of the
  global human immunoglobulin (ph4) for intravenous
  injection (COVID-19) market during the forecast
  period.

5
Figure 1.Global Human Immunoglobulin (ph4) for
Intravenous Injection (COVID-19) Market Value
(US Mn), by Region, 2020
6
Impact of Coronavirus (Covid-19) Pandemic

• The increasing incidence of disease outbreaks is
  escalating demand for advanced diagnostic
  measures, which is expected to boost growth of
  the human immunoglobulin (pH4) for Intravenous
  Injection (COVID-19) market. For instance, the
  coronavirus disease (COVID-19) pandemic is the
  most recent outbreak which was first reported on
  December 31, 2019 in Wuhan, China. The World
  Health Organization declared coronavirus disease
  (COVID-19) as a pandemic on March 11, 2020.
  According to the World Health Organization (WHO),
  around 1,991,562 cases of the coronavirus disease
  (COVID-19) were reported on April 16, 2020 across
  the globe.

7

• Approvals of intravenous human immunoglobulin
  products by regulatory authorities are expected
  to drive the growth of the human immunoglobulin
  (pH4) for intravenous injection (COVID-19) market
  during the forecast period. For instance, in
  September 2017, CSL Behring received the U.S.
  Food and Drug Administration (FDA) approval for
  Privigen, a human immune globulin intravenous
  liquid, indicated for the treatment of adults
  with chronic inflammatory demyelinating
  polyneuropathy (CIDP) to improve neuromuscular
  disability.

8
Market Restraint

• Side effects such as headache, cough, fatigue,
  infusion site reaction, nausea, urticaria,
  sinusitis, blood pressure increased, diarrhea,
  dizziness, and lethargy that are associated with
  human immunoglobulin (pH4) for intravenous
  injection are expected to hinder the market
  growth. For instance, on July 2017, Octapharma
  USA Inc. issued voluntary market withdrawal of
  one lot of Octagam, a human immune globulin
  intravenous liquid, as a result of increased
  hypersensitivity events such as urticaria,
  wheezing and anaphylactoid-type responses.

9
Figure 2.Global Human Immunoglobulin (ph4) for
Intravenous Injection(COVID-19) Market Value
Share (),by Disease Indication,2020
10
Competitive Section

• Major players operating in the global human
  immunoglobulin (pH4) for intravenous injection
  (COVID-19) market are Takeda Pharmaceutical
  Company Limited, Baxter International Inc., CSL
  Behring, Bayer AG, Grifols, S.A., Octapharma AG,
  Shanghai RAAS Blood Products Co., Ltd., Hualan
  Biological Engineering Inc, China Biologic
  Products, Inc., Sichuan Yuanda Shuyang
  Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical
  Group Co., Ltd., ADMA Biologics, Inc., and
  Sinopharm Group Co., Ltd.

11

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Reference
• https//www.coherentmarketinsights.com/market-insi
  ght/human-immunoglobulin-ph4-for-intravenous-injec
  tion-market-3790

12
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

13
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

14

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/